Patents by Inventor Chrisantha Hugh Senanayake

Chrisantha Hugh Senanayake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bupropion Metabolites and Methods of Their Synthesis and Use
    Publication number: 20100125070
    Abstract: Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.
    Type: Application
    Filed: January 22, 2010
    Publication date: May 20, 2010
    Inventors: Kevin Qun FANG, Chrisantha Hugh Senanayake, Paul Grover
  • Methods of treating or preventing pain using sibutramine metabolites
    Patent number: 6974838
    Abstract: Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
    Type: Grant
    Filed: March 23, 2004
    Date of Patent: December 13, 2005
    Assignee: Sepracor Inc.
    Inventors: Chrisantha Hugh Senanayake, Qun Kevin Fang, Zhengxu Han, Dhileepkumar Krishnamurthy
  • Methods of treating or preventing pain using sibutramine metabolites
    Publication number: 20040180857
    Abstract: Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
    Type: Application
    Filed: March 23, 2004
    Publication date: September 16, 2004
    Inventors: Chrisantha Hugh Senanayake, Qun Kevin Fang, Zhengxu Han, Dhileepkumar Krishnamurthy
  • Methods of treating or preventing neuropathic pain using sibutramine metabolites
    Patent number: 6710087
    Abstract: Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: March 23, 2004
    Assignee: Sepracor, Inc.
    Inventors: Chrisantha Hugh Senanayake, Qun Kevin Fang, Zhengxu Han, Dhileepkumar Krishnamurthy
  • Compositions comprising dopamine reuptake inhibitors and methods of making and using the same
    Publication number: 20020183281
    Abstract: Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
    Type: Application
    Filed: June 4, 2002
    Publication date: December 5, 2002
    Applicant: Sepracor Inc.
    Inventors: Chrisantha Hugh Senanayake, Qun Kevin Fang, Zhengxu Han, Dhileepkumar Krishnamurthy
  • Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
    Patent number: 6399826
    Abstract: Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
    Type: Grant
    Filed: January 11, 2000
    Date of Patent: June 4, 2002
    Assignee: Sepracor Inc.
    Inventors: Chrisantha Hugh Senanayake, Qun Kevin Fang, Zhengxu Han, Dhileepkumar Krishnamurthy
  • Bupropion metabolites and methods of their synthesis and use
    Publication number: 20020052341
    Abstract: Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.
    Type: Application
    Filed: November 16, 2001
    Publication date: May 2, 2002
    Applicant: SEPRACOR INC.
    Inventors: Kevin Qun Fang, Chrisantha Hugh Senanayake, Paul Grover
  • Bupropion metabolites and methods of use
    Patent number: 6337328
    Abstract: Methods are disclosed which utilize metabolites of bupropion for treating sexual dysfunction.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: January 8, 2002
    Assignee: Sepracor, Inc.
    Inventors: Qun Kevin Fang, Chrisantha Hugh Senanayake, Paul Grover